Science · Health
Musk has spent years promising to restore sight. A Spanish team already has (and the man who did it urges caution)
While Neuralink announces it will cure blindness within six to twelve months, a Spanish team has already made two blind people perceive shapes and letters, and in China the first commercial brain-computer interface has left the laboratory.
On 3 August 2026, Elon Musk promised again what he has been repeating since 2024: that his Blindsight implant will restore sight imminently. He said it on Ashlee Vance’s podcast, and the Spanish press headlined it “in the coming months”, which is the wording that stuck. It is his favourite promise. It is also, so far, the one with the least evidence behind it. As of today, Neuralink has not implanted Blindsight in a single person, nor published a single peer-reviewed study on vision. Meanwhile, in the Spanish city of Elche, two blind people have already made out shapes and letters again.
Better to say this early, because it runs through the whole story: if we are talking about brain implants for sight at all, it is largely thanks to Musk. None of the other teams here has his megaphone; the field would probably have moved forward without Neuralink anyway, but quietly, with far less money and attention. The question is not whether Musk helps the cause (he does, a lot), but separating what is already real from what is still a promise.
Musk’s promise is the way into a story almost nobody is telling in the right order: brain implants have stopped being science fiction, but the ones that actually work today do not carry his name. A team at the Universidad Miguel Hernández, a public university in Elche, in south-eastern Spain, published its results in November 2025; in China, the first invasive brain-computer interface cleared for commercial use is already being fitted in hospitals; and one very recent precedent explains why any patient should look at these promises calmly. This is what exists today, who is behind it and what stage it is at.
The promise, dated
Musk’s history with blindness is a run of deadlines that keep moving. In September 2024 he announced on X that Blindsight would let people see “even those who were born blind”, so long as the visual cortex is intact. That same month the FDA granted it Breakthrough Device designation, which speeds up the paperwork but is not an approval. In March 2025 he talked about “six to twelve months” for the first vision implants and compared the initial resolution to “the graphics of the first Nintendo”. In May he put the first patient at “the end of this year or the start of next”. In January 2026 he left it “awaiting regulatory approval”. And on 3 August 2026 he repeated the “in the coming months”. The calendar has changed several times; the promise has not.
The promise vs. the reality (2024–2026)
Every date is a fresh promise about Blindsight. The reality, below, has not moved. Tap any milestone to see how much time has passed.
-
17 Sep 2024
“You will see even if you were born blind”
Said on X. That month the FDA grants Blindsight Breakthrough Device designation (it speeds up the paperwork, it is not an approval).
-
6 Mar 2025
“6–12 months” for the first vision implant
At Y Combinator. He compares the initial resolution to “the graphics of the first Nintendo”.
-
20 May 2025
First patient “in late 2025 or early 2026”
At the Qatar Economic Forum.
-
31 Dec 2025
Large-scale production promised for 2026
On X.
-
28 Jan 2026
“Awaiting regulatory approval”
On X. That day, Reuters confirms 21 participants at Neuralink — motor control, not vision.
-
3 Aug 2026
The promise, again
On Ashlee Vance’s podcast. “In the coming months” is how the press headlined it, not a direct quote from him.
Source: Musk’s public statements on X, at Y Combinator and Qatar Economic Forum events and on Ashlee Vance’s podcast — a primary but self-interested source, with no peer-reviewed study and no ClinicalTrials.gov registration behind them; Reuters, 28 Jan 2026; FDA, Sep 2024.
What is actually true at Neuralink
Separate what has been demonstrated from what has been announced. Neuralink does have 21 participants in its trials worldwide (the company confirmed it to Reuters on 28 January 2026), but those trials are about controlling devices with thought: moving a cursor, operating a computer. They are not about vision. Blindsight, the implant for sight, has no human patient yet, is not registered on ClinicalTrials.gov, and there is no peer-reviewed publication from Neuralink on visual restoration. Everything known about Blindsight comes from its founder’s X account. That does not invalidate it, far from it, but it puts it where it belongs: in a very ambitious, hopeful promise, not in the evidence. Plenty of neuroscientists are in fact comfortable with the goal of restoring limited vision when the cortex is intact; what makes them raise an eyebrow is the promise of sight “better than human”, which is another matter entirely.
The turn: what is happening far from Neuralink
Now for the part almost nobody tells. In November 2025, a team at the UMH in Elche, led by Professor Eduardo Fernández Jover with the neurosurgeon Pablo González López (of the Dr Balmis Hospital in Alicante), published in Science Advances the results of implanting electrodes in the visual cortex of two blind people. The participants came to perceive patterns, movement and some letters. This is not natural vision (they are phosphenes, points of light the brain learns to interpret) and it is still research, not a device a patient can ask for.
What a patient with a cortical implant sees
Compare a real scene with its phosphene simulation. Slide to reveal, and change the number of electrodes.
The human eye has between 120 and 130 million photoreceptors. Today’s cortical implants run from dozens — Orion, 60 electrodes — to around 1,000: this is not vision, it is points of light the brain learns to interpret. Source: UMH Elche (Science Advances); Second Sight Orion. Illustrative simulation.
The second focus is China. On 13 March 2026, the Chinese regulator (NMPA) approved the NEO implant (developed with Tsinghua University) as the world’s first invasive brain-computer interface for commercial use. Mind the caveat: NEO does not restore sight; it is designed for people with tetraplegia from a cervical spinal cord injury, and it helps them recover movement in the hand. Its relevance to this story lies elsewhere: a brain implant has left the clinical trial and is already being fitted in ordinary hospitals, which has yet to happen in the United States or the European Union.
Brain implants, by stage of development
Six active projects, one abandoned. Filter by stage, or open each group for the detail.
Commercially approved
Clinical trial
Preclinical
Abandoned
Precision Neuroscience (US, temporary use: 510(k) K242618, March 2025, under 30 days) has no stage comparable to the ones above. Declared gap. There was a patient figure here. I am withdrawing it: the company has no trial registered on ClinicalTrials.gov, and its 510(k) was cleared with no clinical data, only bench testing and animal work.
Declared gap. The Blackrock Neurotech row carried a patient figure. I am withdrawing it: the company has no trials registered in its name on ClinicalTrials.gov and publishes no count of its own. The largest and longest trial of a brain implant of this kind, BrainGate, documents 14 people implanted between 2004 and 2021.
Source: Reuters; NMPA/Xinhua; Science Advances; IEEE Spectrum; ClinicalTrials.gov; FDA (510(k) K242618).
Why caution pays: the Second Sight case
There is a concrete reason not to read these promises as a guaranteed purchase, and it has names. Second Sight gave partial sight back to more than 350 people with its Argus II implant. In 2019 it announced it would stop making the device, in 2020 it stopped supporting it, and in 2022 it merged with another company and vanished as such, leaving those patients with a device inside their heads, no spare parts and nobody to repair it (IEEE Spectrum documented it). One of them, Terry Byland, was the company’s public face for years; this is how he sums up his position today: “As long as it doesn’t break, fine. But if something goes wrong, I’m out of luck, because there is no way to fix it.”
Fantastic technology and a lousy company.
Ross Doerr, Second Sight patient
The useful question about an implant is not only whether it works, but whether it will still be working when the company changes its plans.
What the man who did it says
The line that puts this whole story in order comes from Eduardo Fernández, the Spanish researcher who has actually made two people see:
It is very important to move forward little by little and not create false expectations, because for now this is only ongoing research.
Eduardo Fernández Jover, Universidad Miguel Hernández, Elche (Spain)
His team points blind people towards organisations such as the ONCE, Spain’s national organisation for the blind, and keeps repeating that this is still research. It is the exact counterpoint to the social-media announcement everybody has seen.
The wider frame comes from another Spaniard, the neurobiologist Rafael Yuste, who drove the idea of “neurorights” and is one of the voices behind the León Declaration on European neurotechnology, issued in 2023 during Spain’s presidency of the EU Council: “The brain has to be protected as the sanctuary of our mind, because that is where human identity is generated.” He is not talking about this case in particular, but about the ground it is played on.
What to watch to know whether this is really moving
Four signals, above the noise: that Neuralink registers Blindsight on ClinicalTrials.gov and publishes it in a peer-reviewed journal; that the Elche team goes from two people to a larger clinical trial; that China publishes results from its patients beyond the regulatory announcement; and, above all, the real resolution (making out points of light is not the same as seeing). Until those boxes are ticked, every new “in the coming months” is a date, not a fact.
Where each implant acts: eye → optic nerve → cortex
The chain of vision, and the point where each implant steps in.
Science Advances (UMH Elche); IEEE Spectrum (Argus II). Schematic illustration.
Next time Musk promises to restore sight imminently, the useful question is not whether he will. It is who has already done it (two people in Elche) and what the man who did it asked for in return: no false expectations. And, if the day comes, that the implant stays switched on long after the spotlights go out.
Sources
- UMH / Dr Balmis Hospital (Alicante, Spain) — Science Advances, Nov 2025. DOI 10.1126/sciadv.adv8846. Primary.
- Neuralink via Reuters, 28 Jan 2026 (21 participants). Primary / company statement.
- FDA — Blindsight Breakthrough Device designation, Sep 2024. Primary.
- FDA — 510(k) K242618, Precision Neuroscience’s “Layer 7-T”, cleared on 30 March 2025: temporary use (under 30 days), assessed with bench testing and an animal study, no clinical data. Primary.
- Rubin DB et al., “Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System”, Neurology 100(11):e1177-e1192, 14 March 2023 — DOI 10.1212/WNL.0000000000201707. 14 adults implanted between 2004 and 2021 in BrainGate (NCT00912041), the longest and largest brain implant trial. Primary.
- NMPA (China) / Xinhua — approval of NEO, 13 March 2026. Primary.
- IEEE Spectrum, “Their Bionic Eyes Are Now Obsolete and Unsupported” (2022) — Second Sight / Argus II, more than 350 patients implanted; quotes from Terry Byland and Ross Doerr (“fantastic technology and a lousy company”). Solid secondary.
- Public statements by Elon Musk on X, at Y Combinator, at the Qatar Economic Forum and on Ashlee Vance’s podcast (Sep 2024–Aug 2026) — a primary but self-interested source: no ClinicalTrials.gov registration and no peer-reviewed publication behind them (see “What is actually true at Neuralink”).
- Rafael Yuste — published interviews; León Declaration (2023, Spanish presidency of the EU, 30+ countries). Secondary.
- EurekAlert / MedicalXpress, Nov 2025 — UMH press release. Secondary.